Abstracts tagged "interferon"

Abstract Number: 1775 • ACR Convergence 2025
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
pradeep sosigowda¹, Phani Kumar D¹, Megha Uppin¹ and Liza rajasekhar², ¹NIMS, Hyderabad, Telangana, India, ²Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases primarily affecting skeletal muscle, with potential involvement of other organs. They are classified…
Abstract Number: 0943 • ACR Convergence 2025
Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Haylee Cosgrove¹, Xiaoyan Gong¹, Aidan Matunis¹ and Jeremy Tilstra², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The pathogenesis of systemic lupus erythematosus (SLE) is thought to be strongly influenced by the interferon (IFN) signaling pathway, particularly type I IFNs (IFNα/β).…
Abstract Number: 0508 • ACR Convergence 2025
Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
Clementine Pouenat¹, Marine Vierling², Chiara Meier³, Ludivine Robin⁴, Philippe Kolb⁵, Hartmut Hengel⁶, Gaetane Nocturne⁷, Divi Cornec⁸, Valerie Devauchelle⁹, Véronique Le Guern¹⁰, Claire larroche¹¹, Damien Sène¹², Marion Couderc¹³, Eric HACHULLA¹⁴, Philippe Dieude¹⁵, Olivier Vittecoq¹⁶, Jacques Morel¹⁷, Nicolas Meyer¹⁸, Raphaele Seror¹⁹, Reinhard Voll²⁰, Pierre-Marie Duret²¹, Laurent Miguet²², Xavier Mariette²³ and Jacques-eric GOTTENBERG²⁴, ¹IBMC, UPR ³⁵⁷², STRASBOURG, France, ²Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ³Strasbourg University Hospital, Department ofRheumatology, STRASBOURG, France, ⁴Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁵INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁶INSTITUTE OF VIROLOGY University Hospital Freiburg, FREIBURG, Germany, ⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ⁸LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁹UBO, Brest, France, ¹⁰Cochin hospital, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹²Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie CHU Clermont-Ferrand, Clermont-Ferrand, ¹⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, ¹⁵Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹⁶Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ¹⁷CHU and University of Montpellier, Montpellier, France, ¹⁸Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ¹⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁰University Medical Center Freiburg, Freiburg, Germany, ²¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²²Haemtology, Strasbourg University Hospital, IBMC UPR ³⁵⁷², Strasbourg, France, ²³Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁴Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Fc‐gamma receptor (FcγR) activation by soluble IgG immune complexes (sICs) is considered to play a pivotal pathogenic role in B-cell-mediated autoimmune diseases, such as…
Abstract Number: 2672 • ACR Convergence 2025
Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
Can Xia¹, Wanlong Wu¹, Yan Ye¹, Jingjing Li², Runci Wang¹, Wenwen Xu³, Zhiwei Chen¹, Yakai Fu², Xia Lyu¹, Kaiwen Wang¹, Wei Fan¹, Jia Li¹, Xiaodong Wang², Shuang Ye⁴ and Qiong Fu⁵, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5+DM) is a distinct and severe subtype of dermatomyositis, frequently complicated by interstitial lung disease (ILD). Among…
Abstract Number: 1770 • ACR Convergence 2025
Brepocitinib Inhibits Key Pathogenic Cytokine Signaling in Dermatomyositis Patients
Christina Charles-Schoeman¹, Yessar Hussain² and Brendan Johnson³, ¹UCLA Medical Center, Santa Monica, CA, ²Austin Neuromuscular Center, Austin, TX, ³Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease of the skin and muscles with significant unmet need and limited treatment options. Brepocitinib is an oral,…
Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Arielle Glatman Zaretsky¹, Carley Tasker¹, Pablo Abreu¹, Ciara Torres², Li-Hong Ben¹, Scott MacDonnell¹, Andre Limnander¹ and Jamie Orengo¹, ¹Regeneron, Tarrytown, NY, ²Regeneron, Tarrytown
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 2670 • ACR Convergence 2025
Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.
Miriam Retuerto Guerrero¹, Clara Moriano², Ana Pareja-Martínez³, Natalia Molina-Esteban⁴, Jose Puig-Buendia⁵, Concepción Postigo-Llorente⁵, Ana Lopez-Ceron Cofiño⁶, Julia Martínez Barrio⁷, Paola Vidal-Montal⁸, Elena Sendagorta Cudos⁹, GUILLERMO GONZALEZ ARRIBAS¹⁰, Jaime Calvo¹¹, Juan Ramon De Dios¹², Juan María Blanco-Madrigal¹³, Paloma Vela Casasempere¹⁴, Javier Bachiller¹⁵, Concepción Fito-Manteca¹⁶, Carmen Ordas calvo¹⁷, Luisa Martos Cabrera¹⁸, Alejandro Sanchez Herrero¹⁹, Luis Ortega-Valin²⁰ and Elvira Diez Alvarez²¹, ¹Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, ²Hospital León, LEON, Castilla y Leon, Spain, ³Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, ⁴Rheumatology. Hospital Universitario ¹² de octubre, Madrid, Madrid, Spain, ⁵Dermatology. Hospital universitario ¹² de octubre, Madrid, Madrid, Spain, ⁶Rheumatology. Complejo Asistencial Universitario de Soria, Soria, Castilla y Leon, Spain, ⁷Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ⁸Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ⁹Dermatology. Hospital universitario La Paz, Madrid, Madrid, Spain, ¹⁰Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹¹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹²Department of Rheumatology. Hospital Universitario Araba. Instituto de Investigación Sanitaria BIORABA., Vitoria, Pais Vasco, Spain, ¹³Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, ¹⁴Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Ramon y Cajal, Madrid, Madrid, Spain, ¹⁶Rheumatology. Hospital Universitario de Navarra., Pamplona, Navarra, Spain, ¹⁷Rheumatology. Hospital Universitario de Cabueñes., Gijon, Asturias, Spain, ¹⁸Dermatology. Hospital Universitario de La Princesa, Madrid, Madrid, Spain, ¹⁹Dermatology. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ²⁰Pharmacy. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ²¹Rheumatology. Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease marked by muscle weakness and characteristic cutaneous manifestations. Dysregulation of the Type I interferon (IFN-I) pathway plays…
Abstract Number: 1771 • ACR Convergence 2025
Interferon- α, Anti-Interferon-Alpha Antibodies and Disease Activity in Systemic Lupus Erythematosus
Gollakota Nandita¹, Kambhampati Sreelekha², Kaushik Puranam³, Phani Kumar D⁴, Meghna Gavali⁵ and Liza rajasekhar⁶, ¹NIMS, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, ⁴NIMS, Hyderabad, Telangana, India, ⁵nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ⁶Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease, partly driven by Interferon-alpha (IFN-α). Studies suggest that anti-IFN-α antibodies (AIAA) may neutralize IFN-α, potentially…
Abstract Number: 0929 • ACR Convergence 2025
SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
Martin Jakobsen¹, Pernille Noer², Kristina Byskov³, Emil Nilsson⁴, Laura Ryø⁵, Claus Olesen² and Richard BETHELL⁶, ¹Aarhus University, Aarhus, Denmark, ²Sulis Therapeutics, Aarhus, Denmark, ³Notify Therapeutics, Aarhus, Denmark, ⁴Sulis Therapeutics, Aarhus C, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Sulis Therapeutics, Stockholm, Sweden
Background/Purpose: STING plays a critical role at the intersection of innate and adaptive immunity and has been linked to the pathogenesis of SSc and SLE.…
Abstract Number: 0301 • ACR Convergence 2025
Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release
Sabrina Helmold Hait¹, Mary Maclean², Cindy Phung³, Gustaf wigerblad⁴, Iago Pinal Fernandez⁴, Carl Esperanzate⁵, hongying Wang⁵, Andrew Mammen⁶, willian Gahl⁵, Daniel L. Kastner⁷, Stefania Dell'orso⁴, Danica Novacic⁵, massimo Gadina⁴ and Ivona Aksentijevich⁸, ¹NIAMS/NIH, Bethesda, MD, ²NIH-NIAMS, Rockville, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, ⁸¹⁰⁰, Bethesda, MD
Background/Purpose: The mevalonate (MVK) pathway synthesizes isoprenoids that mediate post-translational protein modifications via prenylation. Deficient protein prenylation due to decreased mevalonate kinase (MK) activity leads…
Abstract Number: 2668 • ACR Convergence 2025
CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit
Nazgol Haddadi¹, Khashayar Afshari¹, Yuqing Wang¹, Carolina S. Lopes¹, Chee-Huat L. Eng², Nuria Martinez-Gutierrez¹, Leah Whiteman¹, Kevin Wei³, Kirsten Frieda², Stefania Gallucci¹, Misha Rosenbach⁴, Ruth Ann Vleugels⁵, John E. Harris¹, Manuel Garber¹ and Mehdi Rashighi¹, ¹UMass Chan Medical School, Worcester, MA, ²Spatial Genomics, Inc., Pasadena, CA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's Hospital, Chestnut Hill, MA
Background/Purpose: Inflammatory skin diseases vary widely in symptoms and causes. While ultraviolet (UV) light helps treat some like vitiligo and psoriasis, in conditions like cutaneous…
Abstract Number: 1755 • ACR Convergence 2025
Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
Zoya Qaiyum¹, Michael Tang², Shirin Soleimani³, Addison Pacheco², Melissa Lim⁴, Fataneh Tavasolian⁴, Trevor Pugh³ and Robert Inman², ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. We…
Abstract Number: 0920 • ACR Convergence 2025
Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Elizabeth Morgan¹, Bin Lin², Sara alehashemi¹, Adriana de Jesus¹, Keith Kauffman³, Christopher Friend¹, Farzana Bhuyan¹, Kader Gedik¹, Kat Uss¹, Lauren Krausfeldt⁴, Jason Brenchley⁵, Zoran Gucev⁶, Kathryn Cook⁷, Vafa Mammadova⁸, Gulnara Nasrullayeva⁸, Mariana Correia Marques⁹, Abigail Bosk¹⁰, Brian Nolan¹¹, Scott Canna¹², Maude Tusseau¹³, Andrea Bohrer¹⁴, Katrin Mayer-Barber¹⁵, Timothy Moran¹⁶, Andrew Oler⁴, Daniel Barber³ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ²NIH, Bethesda, MD, ³T-Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, ⁴Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, ⁵Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, ⁶University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ⁷Akron Children’s Hospital, Akron, OH, ⁸Azerbaijan Medical University, Baku, Azerbaijan, ⁹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Children’s National Hospital, Washington DC, ¹¹Lurie Children’s Hospital, Chicago, ¹²Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Hôpital Femme-Mère-Enfant, Bron, France, ¹⁴Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ¹⁵Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), Bethesda, MD, ¹⁶University of North Carolina School of Medicine, Chapel Hill, NC
Background/Purpose: NEMO-deleted 5 autoinflammatory syndrome (NEMO-NDAS) is an inflammatory disease caused by mosaic splice-site variants that lead to exon 5 skipping in IKBKG, encoding NEMO.…
Abstract Number: 0286 • ACR Convergence 2025
Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients
Connor Buechler¹ and David Pearson², ¹University of Minnesota, Mendota Heights, MN, ²Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune connective tissue disorder with a chronic, relapsing course that can persist into adulthood. Current therapies exhibit widely variable…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].